Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XL-888 by Exelixis for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
XL-888 by Exelixis for Colorectal Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
XL-888 by Exelixis for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to...
XL-888 by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
XL-888 by Exelixis for Small Intestine Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Small Intestine Cancer. According to GlobalData, Phase...
XL-888 by Exelixis for Hepatocellular Carcinoma: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...
XL-888 by Exelixis for Gastric Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...